Clinical trials on Myasthenia Gravis

Understanding Myasthenia Gravis

Myasthenia Gravis (MG) is a chronic autoimmune disorder characterized by weakness and rapid fatigue of any of the muscles under your voluntary control. It’s caused by a breakdown in the normal communication between nerves and muscles. There is no cure for MG, but treatment can help relieve signs and symptoms, such as weakness of arm or leg muscles, double vision, drooping eyelids, and difficulties with speech, chewing, swallowing, and breathing.

Key Features of Myasthenia Gravis

  • Autoimmune Disorder: In MG, the immune system produces antibodies that interfere with the muscle cells’ ability to receive signals from the nerve cells.
  • Variable Symptoms: The severity of the symptoms can vary greatly among individuals; they may include muscle weakness, drooping eyelids, double vision, and difficulties with speech, chewing, swallowing, and breathing.
  • Treatment Options: While there’s no cure for MG, treatments are available that can help manage the symptoms. These may include medications, such as cholinesterase inhibitors and immunosuppressants, and therapies like plasmapheresis and intravenous immunoglobulin.


Myasthenia Gravis is a complex condition that requires careful management and a multidisciplinary approach to treatment. With the right support and treatment plan, many individuals with MG can lead active and fulfilling lives. Awareness and understanding of the disease are crucial for early diagnosis and effective management.

Prognosis for Myasthenia Gravis

Myasthenia Gravis is a chronic autoimmune disorder characterized by muscle weakness and fatigue. The long-term prospects for individuals with Myasthenia Gravis have improved significantly with advances in medical care. While the condition is considered lifelong, the degree of muscle weakness varies among patients and can fluctuate over time. Periods of remission are common, where symptoms may improve, and with careful management, the maintenance of daily activities is often possible. The prognosis is generally favorable, and many patients lead full lives, although close monitoring is essential to manage the variability of symptoms. Life expectancy is typically not affected, but quality of life can be impacted without proper management. It should be noted that while some individuals may experience only mild symptoms, others may face more significant challenges. Regular consultations with healthcare providers are crucial to optimize the long-term outlook for those living with Myasthenia Gravis.

Complications in Myasthenia Gravis

Myasthenia Gravis can lead to various complications that may impact daily life. A significant concern is the weakening of respiratory muscles, which can cause breathing difficulties. This might result in less oxygen reaching the body, causing fatigue or shortness of breath. Swallowing problems are also common, increasing the risk of choking or aspiration, where food or liquid enters the lungs, potentially leading to pneumonia. Additionally, the condition can affect facial and eye muscles, resulting in drooping eyelids and blurred or double vision, which can interfere with routine activities such as reading or driving. Muscle weakness may extend to the arms and legs, making it challenging to perform tasks requiring strength and coordination. These complications can reduce independence and overall quality of life, as everyday activities become more difficult to manage.

Treatment Methods for Myasthenia Gravis

For the management of Myasthenia Gravis, the incorporation of certain lifestyle adjustments can be beneficial. A diet rich in potassium, such as bananas and leafy greens, is often recommended. Small, frequent meals may help conserve energy. Regular physical activity, tailored to individual tolerance levels, may improve overall muscle strength and fatigue management.

Pharmacotherapy options include medications that enhance communication between nerves and muscles or suppress the immune system’s abnormal response. These are not experimental drugs but standard treatments that may be adjusted based on patient response and physician guidance.

Modern technology offers tools like speech synthesizers for those experiencing difficulty speaking and computer programs that can assist with daily tasks. Additionally, electric mobility aids can help maintain independence in individuals with mobility challenges.

Consultation with healthcare professionals is important before making any changes to treatment plans. They can provide personalized advice and support for effective management of Myasthenia Gravis.

  • CT-EU-00041941

    Testing gefurilimab treatment in patients with myasthenia gravis

    This study is looking at a potential treatment for a disease called generalized myasthenia gravis (gMG) in adults. It’s called gefurulimab (ALXN1720). For our study, researchers will divide participants into two groups, each of which will be treated differently. One group will receive the new drug. Importantly, the researchers conducting the study will not know who received which treatment. This ensures the fairness and accuracy of the results. Participants’ health will be closely monitored to ensure that ALXN1720 is safe. The main goal is to check whether new mediations are effective. It will be measured by checking whether patients’ condition has improved compared to when the study started. This will take approximately 26 weeks.

    • gefurulimab/ALXN1720
  • Testing Nipocalimab’s effect on adults with Muscle Weakness

    This study is about a new drug called nipocalimab for patients with a disease called Myasthenia Gravis (MG). MG patients feel weak in their muscles, and nipocalimab potentially could help to lessen this weakness. The drug functions by attaching itself to certain components of the blood to lessen the reaction causing muscle weakness. This large-scale study will take place in multiple hospitals and is organized in different phases including initial checks (4 weeks), treatment (24 weeks) and follow-ups (up to 2 years). It will be measured how well the treatment works through daily activity scores and strength tests.

    • Nipocalimab
  • Long-term safety of efgartigimod in myasthenia gravis

    The purpose of this trial is to assess the long-term safety of efgartigimod, both intravenously and subcutaneously, in individuals who participated in the previous studies (ARGX-113-2006 and ARGX-113-2207) for generalized myasthenia gravis (gMG). The goal is to ensure the ongoing safety of the drug over an extended period and to monitor any potential side effects.

    • Efgartigimod
  • Testing efgartigimod safety and effects in kids with Myasthenia Gravis

    This study is testing a drug called Efgartigimod in children with a specific disease called generalized myasthenia gravis. In the study, medicine is injected into the body. The purpose of this study is to see how the body deals with this medicine and whether it works and is safe for children aged 2 to just under 18 with this disease. The experiment will last approximately 28 weeks, with some testing the dose for 8 weeks and others for 18 weeks. During the study, children donate blood so that researchers can measure the presence of the drug and the presence of a specific protein in the blood.

    • Efgartigimod
  • New study for myasthenia gravis patients: inebilizumab’s effects

    This clinical trial is evaluating the effects of inebilizumab on patients with myasthenia gravis, an autoimmune disorder affecting muscle strength. The study, involving 270 participants, is designed to determine if inebilizumab is more effective than a placebo in improving daily life activities and muscle strength. Participants will receive intravenous doses of inebilizumab or placebo and may enter a longer observation phase to assess long-term effects. The goal is to improve treatment for myasthenia gravis by assessing improvements in daily functions and tracking any side effects.

    • Inebilizumab
  • The efficacy and safety of satralizumab in generalized Myasthenia Gravis

    This is an investigation into the use of satralizumab, a drug aimed to treat patients suffering from a condition known as Generalized Myasthenia Gravis (gMG), a neurological disorder causing weaknesses in various muscles. The trial focuses on understanding how safe and effective satralizumab is for these patients. This involves observing any changes in patients’ daily living activities, and quality of life, over a 24-week period. These patients are administered either the drug or a placebo via subcutaneous injection (under the skin injection) on a regular schedule. The impact of the drug will be monitored through various quality of life and symptom severity scores.

    • Satralizumab